Get access

Randomized controlled trial of memantine in dementia associated with Parkinson's disease§

Authors

  • Iracema Leroi MD, FRCPC, MRCPsych,

    Corresponding author
    1. Consultant in Old Age Psychiatry/Honorary Senior Lecturer, Lancashire Care Trust, Royal Blackburn Hospital, Blackburn, United Kingdom
    2. Department of Psychiatry and Behaviourial Sciences, University of Manchester, Manchester,United Kingdom
    • Consultant in Old Age Psychiatry/Honorary Senior Lecturer, Lancashire Care Trust, Royal Blackburn Hospital, Haslingden Road, Blackburn, BB2 3HH, United Kingdom
    Search for more papers by this author
  • Ross Overshott MB, ChB, MRCPsych,

    1. Consultant in Psychological Medicine, Pennine Care NHS Foundation Trust, Royal Oldham Hospital, Rochdale, United Kingdom
    Search for more papers by this author
  • E. Jane Byrne MD, FRCPsych,

    1. Senior Lecturer in Old Age Psychiatry, University of Manchester, Manchester, United Kingdom
    Search for more papers by this author
  • Emily Daniel BSc,

    1. Assistant Psychologist, Manchester Mental Health and Social Care Trust, Manchester, United Kingdom
    Search for more papers by this author
  • Alistair Burns MD, MPhil, FRCP, FRCPsych

    1. Professor of Old Age Psychiatry, University of Manchester, Manchester, United Kingdom
    Search for more papers by this author

  • This study was presented as a poster (Guided Tour 2) at the Twelfth International Congress of Parkinson's Disease and Movement Disorders, Chicago, 2008 (poster #600).

  • The authors take full responsibility for the content of the manuscript. This study was sponsored by an unrestricted grant from Lundbeck, Inc., which means that the conceptualization, design, undertaking, analysis, and manuscript preparation were undertaken entirely by the authors. We have given Lundbeck, Inc., full access to the manuscript; however, they have not seen the raw data. None of the authors is federal employees in the USA or United Kingdom and there is no previous copyright on the manuscript.

  • §

    Potential conflict of interest: Drs. Leroi and Byrne and Prof. Burns have received honoraria for presentations from H. Lundbeck A/S. Dr. Leroi has received an unrestricted grant from H. Lundbeck A/S for this study (see Acknowledgments).

Abstract

The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD. © 2009 Movement Disorder Society

Get access to the full text of this article

Ancillary